SOPHiA GENETICS SA

SOPHiA GENETICS SA, à Rolle, CHE-184.818.745 (FOSC du 19.12.2024, p. 0/1006210663). Statuts modifiés le 18.06.2025. L'assemblée générale a modifié deux clauses statutaires relatives à une augmentation conditionnelle du capital (selon décision du 26.06.2023) par décision du 18.06.2025. Pour les détails, voir les statuts. L'assemblée générale a modifié une clause statutaire relative à une marge de fluctuation du capital-actions (selon décision du 26.06.2023) par décision du 18.06.2025;
pour les détails, voir les statuts. PricewaterhouseCoopers SA (CHE-497.306.752) a transféré son siège à Lausanne.

"Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 09.05.2025/nPublicly viewable until: 09.05.2026/nPublication number: UP04-0000007157/nPublishing entity/nSOPHiA GENETICS SA, Zone artisanale La Pièce 12.

1180 Rolle/nInvitation to the ordinary general meeting SOPHiA/nGENETICS SA/nOrganisation concerned:
/nSOPHiA GENETICS SA/nCHE-184.818.745/nZone artisanale La Pièce 12/n1180 Rolle/nGeneral meeting details:/n18.06.2025, 14.00 Uhr, Offices of SOPHiA GENETICS SA, La Pièce 12, 1180 Rolle/VD,/nSwitzerland/nInvitation/Agenda:/n1. 2024 Management Report, Annual Financial Statements and Consolidated Financial/nStatements, Auditors' Reports/n2. Consultative Vote on the 2024 ESG Impact Summary (Sustainability Report)/n3. Discharge of the members of the Board of Directors and the Executive Committee/n4. Appropriation of 2024 Financial Results/n5. Re-election of the Chair;
re-election of the members of the Board of Directors/na. Re-election of Troy Cox (as Chair and member of the Board)/nb. Re-election of Jurgi Camblong (as member of the Board)/nc. Re-election of Tomer Berkovitz (as member of the Board)/nd. Re-election of Jean-Michel Cosséry (as member of the Board)/ne. Re-election of Kathy Hibbs (as member of the Board)/nf. Re-election of Didier Hirsch (as member of the Board)/ng. Re-election of Vincent Ossipow (as member of the Board)/n6. Re-election of the members of the Compensation Committee/na. Re-election of Kathy Hibbs/nb. Re-election of Jean-Michel Cosséry/nc. Re-election of Vincent Ossipow/n7. Election of the Independent Proxy/n8. Re-election of the Statutory Auditors/n9. Approval of the Compensation of the Board of Directors and the Executive Committee/na. Approval of the maximum aggregate amount of compensation of the Board of/nDirectors until completion of the 2026 Annual General Meeting/nb. Approval of the maximum aggregate amount of fixed compensation of the Executive/nCommittee for 2026/nc. Approval of the maximum aggregate amount of variable compensation of the/nExecutive Committee for 2025/n10. Amendments to the Articles of Association/na. Capital Range (or Band)/nb.

Conditional Share Capital/nTo the shareholders of SOPHiA GENETICS SA (Nasdaq SOPH) (the Company)/nInvitation to the Annual General/nMeeting/nDate and Time:
Wednesday, June 18, 2025.

at 8:
00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CEST/nLocation: Offices of SOPHiA GENETICS SA, La Pièce 12, 1180 Rolle, Switzerland/n(AGM 2025)/n1/nDear Shareholders,/nSOPHiA GENETICS was founded in 2011 by a team of biologists and data scientists. At the time, we/ndreamed of a world in which data and analytics would transform patient care. A world in which/ndiscoveries and insights are shared across institutions. And a world in which all patients across the globe/nhave equal access to these insights and, in turn, to the best possible care./nIn 2024, AI created transformative change across industries, from self-driving cars to generative AI to/nvirtual assistants. Despite this, healthcare has lagged in many ways. While cars have learned to drive/nthemselves over the last few years, patient treatment has remained largely the same./nBuilding impactful AI in healthcare comes with unique challenges. Human biology is deeply complex./nThe playing field is small, literally at the molecular level. And the parameters for analysis are in a/nconstant state of fundamental change. Building AI for self-driving cars is difficult, but the rules are/nlargely set. The roads are paved and marked. The turns are perceivable. The physical space is understood/nand well-defined./nWhile challenges to building effective AI in healthcare exist, the mission is not impossible.

It requires/nthree ingredients:
a deep understanding of biology, advanced algorithms, and large datasets, which are/nalso diverse, real-time, and real-world. At SOPHiA GENETICS, we satisfied these requirements to build/nthe most widely used AI Platform in healthcare today./nWe acquired the ingredients for success in a unique way - by cultivating a community of users who love/nusing the SOPHIA DDM? Platform. Today, top biologists across 800+ institutions and 70+ countries log/non daily to analyze and interpret human disease. They contribute their knowledge and expertise in the/nform of insights, which fuel the Platform's AI and create an invaluable engine for analytics. They also/nupload a constant stream of over 350,000 patient profiles annually, exposing the Platform's AI to diverse,/nreal-time, real-world data that further improves its analytical capabilities./nSOPHIA DDM? is ushering in a new era of medicine by using AI to transform patient care. The/nPlatform also fulfills our promise of giving all patients across the globe equal access to the best possible/ncare. Since inception, 1.9 million patients have benefited from this technology. However, this impact was/nnot by chance. I sincerely thank the dedicated team of SOPHiANs who have been working on this/nmission for over a decade. I also thank our customers, partners, and shareholders for joining us on this/ncritical journey./nAs we turn to the future, we have one relentless focus - growth, growth, and more growth. While revenue/nin 2024 was softer than we would have liked, our progress during the year has laid a strong foundation for/nour future success. We refueled the Company's growth by launching an exciting suite of new products/nand signing a record number of new customers, while making meaningful improvements to operating/nexpenses and gross margin./nAs we look ahead, we will remain focused on our six strategic pillars for long-term, sustainable growth. I/nam excited to share more details on our 2024 progress along each of these pillars./nAccelerating adoption of SOPHIA DDM? by landing new clinical customers/nHealthcare institutions around the world continue to choose SOPHIA DDM? for very good reasons, for/nexample, the Platform's top analytical performance, ability to expedite turnaround time, expansive menu,/nand cost-effectiveness./n2/nI am thrilled to announce that we landed a record 92 new core genomics customers in 2024. These/ninstitutions are joining a community of the top names in healthcare, gaining access to a collective/nintelligence that includes 5 of the 7 top cancer hospitals in the world./nOne area we continue to focus on is growth in the US, as the market offers immense potential for growth./nI was proud to see our US customer list grow in 2024. Our list of US customers now includes top names/nsuch as Mount Sinai and Mayo Clinic, two premier healthcare institutions in the US. This success is/ndriving meaningful results. Clinical revenue grew 23% in the US in 2024, and analysis volume grew 26%./nAs I consider our progress over the last 3 years, I can't help feeling that we've reached an inflection point./nWorld-class institutions continue to join our network and volumes continue to grow materially. I look/nforward to keeping you updated on our progress throughout the year./nExpanding usage of SOPHIA DDM? within our existing customer base/nWe continue to employ a ""land and expand"" commercial strategy that focuses on winning new customers/nand then driving usage of our Platform by encouraging those customers to adopt more and more SOPHIA/nDDM? applications over time./nIn 2024, we continued to delight our customers and, in doing so, expand within accounts. We recorded an/nimpressive Net Promoter Score of 67, an achievement we are very proud of. We are also proud that our/ncustomers continue to adopt more applications once joining our network. As of the end of 2024, 58% of/ncustomers used two or more applications, up from 56% a year ago. 36% of customers used three or more/napplications, up from 31% a year ago. And 21% of our customers used four or more applications. The/ncontinued proof of our ability to expand within existing customers exemplifies the importance of landing/nnew customers across the globe./nBuilding SOPHIA DDM?'s menu of offerings/nAt SOPHiA GENETICS, innovation is part of our DNA. We believe in customer-centric innovation,/nlistening to customers and meeting their needs with new and exciting applications."

SOPHiA GENETICS SA, à Rolle, CHE-184.818.745 (FOSC du 26.07.2024, p. 0/1006095309). Signature collective à deux est conférée à Cardoza George, des USA, à Miami (USA), directeur.